BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Alzheimer’s disease

  New Wave of Alzheimer’s Therapies Actively Engage the Immune System

  Active immune therapies hold promise for preventing or slowing disease onset, but some experts warn of potential safety risks.

  August 5, 2024

   · 

  5 min read

   · 

  Gail Dutton
• 

  Opinion

  Cell and Gene Therapy Shows Early Promise Against Alzheimer’s—But Challenges Remain

  Longeveron and Lexeo Therapeutics are working on CGT therapies to treat Alzheimer’s disease, but it’s not clear whether they have a better chance of success than traditional approaches.

  August 5, 2024

   · 

  4 min read

   · 

  Jia Jie Chen
• 

  CRISPR

  Small Enzymes, Giant Leaps: CRISPR’s Next-Generation Approach to Genetic Diseases

  Ultracompact CRISPR systems, which are in some cases one-third the size of Cas9, are being designed to be more specific and enable in vivo gene editing in difficult to reach tissues.

  August 5, 2024

   · 

  4 min read

   · 

  Greg Slabodkin
• 

  Earnings

  BioNTech’s Losses Jump Fourfold in Q2 Amid COVID-19 Cliff, Shift to Cancer

  BioNTech on Monday reported nearly $885 million in losses in the second quarter of 2024, compared to $208.5 million during the same period last year.

  August 5, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Bayer’s Finerenone Hits Primary Endpoint in Phase III Heart Failure Trial

  With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.

  August 5, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Business

  Big Pharma-Backed Ribon Therapeutics Shuts Down Business Operations

  Despite having an impressive roster of high-profile supporters, including AbbVie, BMS, J&J, Novartis and Pfizer, PARP-focused Ribon has called it quits after nearly a decade in business.

  August 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Adcomms

  Zevra Gains Support of Adcomm, Clears Hurdle for Potential Rare Disease Approval

  An FDA advisory committee agreed on Friday that Zevra Therapeutics had provided sufficient efficacy data supporting the approval of arimoclomol for Niemann-Pick disease type C.

  August 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug shortages

  Lilly’s Mounjaro and Zepbound No Longer on FDA Drug Shortage List

  All doses of Eli Lilly’s type 2 diabetes medication Mounjaro and weight-loss drug Zepbound are now available, according to an update on Friday to the FDA’s drug shortage database.

  August 5, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody

  As part of a pipeline realignment, Bristol Myers Squibb is returning the rights to Agenus for its proprietary TIGIT bispecific antibody program and terminating their 2021 license, development and commercialization agreement.

  August 5, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• Press Releases

  MIP Discovery rebrands as Tozaro as it completes transition to supporting cell and gene therapy viral vector analytics and purification

  Tozaro’s rationally designed smart polymer affinity reagents offer novel analytics and purification solutions to enhance the development and manufacture of viral vectors in cell and gene therapy Rebrand follows Series A funding round in February 2024

  August 5, 2024

   · 

  2 min read